Clinical Trials

Individuals may qualify to participate if they:

Are ≥18 years of age.
Have been diagnosed with chronic rhinosinusitis
Have ethmoid and maxillary sinus disease with or without frontal, and/or sphenoid disease.
Have a baseline sinus CT scan (taken within 6 months of study enrollment)
Have been nonresponsive to medical management (trial of antibiotics; plus trial of oral or nasal corticosteroids).

Length of study: 12 months
Number of visits: 5
Compensation for time and travel

For more information:

Dr. John Lanza – Port St. Lucie office, contact Erica Riccard at This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr. Scott Powell – Brandon office, contact Ciarra Kennedy at This email address is being protected from spambots. You need JavaScript enabled to view it.

Candidates must be between 18-75 years of age
Has a diagnosis of probable or definite Ménière's Disease
At least two of three active symptoms (fluctuating hearing; tinnitus; aural fullness; vertigo or dizziness) of Ménière's disease.
Cannot have significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurological or psychiatric disease.
- Length of study: 6 or 12 months
- Oral medication
Study drug, exams, diagnostic tests, and blood work are covered and are free of charge to the patient
Compensation for time and travel

Study conducted by:

Principal Investigator – Mark H. Widick, MD
Sub-Investigator – Diana del Valle, MD
5130 Linton Blvd., Suite E2, Delray Beach, Florida 33484

If you want further information concerning this study, contact

Delphine Coles at 561-939-0186 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Clinical Study of NEUROMARK® System in Patients with Chronic Rhinosinusitis (CRS)